IncellDx and Kindstar Global announced recently that they have signed master collaboration and exclusive distribution agreements for three of IncellDx's single-cell immuno-oncology and oncology diagnostic products for China. 

As part of the agreement, Kindstar will use Menlo Park, California-based IncellDx's tests — OncoTect iO Tumor Treatment Profile, OncoTect iO Bladder, and OncoBreast — in its laboratory system in China, including Hong Kong and Macao. The OncoTect iO Tumor Treatment Profile identifies PD-L1 expression as well as EGFR and ALK mutations; OncoTect io Bladder identifies bladder cancer and PD-L1 status from urine; and OncoBreast identifies ER, PR, HER2 protein, HER2 mRNA, and aneuploidy DNA simultaneously in breast samples. 

According to IncellDx, users can perform the assays in high throughput in less than three hours. 

"We are excited to broaden our presence in China with Kindstar, from whom we have seen tremendous growth over the years," IncellDx CEO and Founder Bruce Patterson said in a statement. "The scalability of our assays will make this opportunity a major growth driver for IncellDx in 2019 and beyond."

Financial details of the agreement were undisclosed.